Goldman Sachs’s Mateon Therapeutics MATN Stock Holding History
Bought
Maintained
Sold
Other funds holding MATN
Goldman Sachs's MATN Position: Q4 2016 in Review
Goldman Sachs sold out of Mateon Therapeutics (MATN) in Q4 2016, closing a stake of 27,151 shares — an estimated $17K sold.
Goldman Sachs first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $17K in Q3 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.
- Goldman Sachs reported no remaining Mateon Therapeutics position as of Q4 2016 after selling out during the quarter.
- Goldman Sachs sold 27,151 Mateon Therapeutics shares in Q4 2016, an estimated $17K.
- Goldman Sachs first reported a position in Mateon Therapeutics in Q2 2016 and held it in 2 quarters.
- Goldman Sachs's Mateon Therapeutics position peaked at $17K in Q3 2016.
- 1 fund tracked by Wall St. Rank held Mateon Therapeutics as of Q4 2016.
Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.